Is Washington Building a Blueprint for MFN Through Trade Policy?

Something interesting is happening in pharmaceutical policy, and executives should be paying attention.

We are hearing growing calls for Washington to pursue an agreement with Germany similar to the U.S.–UK pharmaceutical arrangement as part of the ongoing Section 301 investigation into German drug pricing.

At first glance, this looks like another trade dispute. The bigger question is whether we are beginning to see a potential blueprint for pursuing the goals behind Most Favored Nation drug pricing.

What is happening?

In June, the U.S. Trade Representative opened a Section 301 investigation into Germany's pharmaceutical pricing and reimbursement practices. USTR wants to determine whether what it calls Germany's “persistent underpayment” for innovative medicines is unreasonable or discriminatory and burdens U.S. commerce.

That is unusual because Section 301 is a trade enforcement tool. Germany's drug reimbursement system, on the other hand, is part of its domestic healthcare system.

The U.S. is essentially asking whether decisions made inside another country's healthcare system can create an unfair burden on American commerce.

Now comes the interesting part. Rather than simply looking toward trade retaliation, there are growing calls for a negotiated solution similar to the one reached with the UK.

The UK may have shown us the model

The U.S.–UK agreement connected pharmaceutical pricing directly with trade.

The UK agreed to increase the net price paid by the NHS for prospective new medicines by 25 percent, increase spending on new medicines over time and limit certain pharmaceutical repayment rates. In return, the United States provided significant protections from pharmaceutical tariffs.

Importantly, the agreement itself connects those commitments to U.S. Most Favored Nation policies.

That makes what is happening with Germany worth watching.

In July, I discussed this possibility with Melanie Whittington at the Leerink Center for Pharmacoeconomics. We talked about whether the U.S.–UK arrangement could become a template for Germany.

My view was that it could be a political template, but Germany would be a harder test. Germany has a different statutory reimbursement system, operates through AMNOG and sits within the European Union.

We may now be seeing that test begin.

Where does MFN fit?

The basic argument behind MFN is relatively simple.

The United States believes Americans pay too much for medicines while other wealthy countries pay too little, leaving the U.S. market carrying a disproportionate share of the cost of pharmaceutical innovation.

There are two ways to narrow that gap.

Washington can try to bring American prices closer to those paid overseas. Or it can try to move prices overseas closer to those paid in America.

The UK agreement demonstrates that Washington is willing to work on the second side of that equation. The Germany investigation may tell us whether that approach can be repeated.

That does not mean Section 301 is MFN. Nor has USTR announced that trade enforcement is the mechanism through which MFN will be implemented.

But it raises an important possibility: trade policy may become one of the tools Washington uses to pursue the broader economic objective behind MFN.

Why should executives care?

If you run a pharmaceutical or biotech company, this changes the way international pricing risk should be viewed.

Germany is still Germany. The UK is still the UK. France, Italy, Spain and other markets continue to have their own reimbursement systems, budget pressures and approaches to determining value.

Those decisions may no longer remain entirely within those national systems.

U.S. trade policy could become another factor.

That has potential implications for launch sequencing, market access, reference pricing, revenue assumptions and investment decisions. A decision that once looked like a German reimbursement issue could eventually have consequences for a company's broader global strategy.

If Germany ultimately reaches an arrangement resembling the UK deal, the obvious question will be what country comes next.

The bigger signal

This is the type of development we look at closely at Lanton Strategies International.

Not because every Section 301 investigation will change pharmaceutical markets, but because understanding what is happening often requires looking across policy silos.

MFN looks like U.S. drug pricing policy. AMNOG looks like German reimbursement policy. Section 301 looks like trade policy. The U.S.–UK agreement looks like a bilateral trade arrangement.

The important part is the connection between them. What happens in reimbursement is beginning to influence trade policy, and trade policy may, in turn, influence how countries approach drug pricing.

We do not yet know whether Germany will result in another UK-style agreement. But if it does, pharmaceutical executives may need to reconsider how they think about global pricing risk.

The bigger question we have to consider is how Washington brings prices overseas closer to those paid in the United States.

Independent analysis from Lanton Strategies International. This article does not constitute legal advice.

The New Risk Map for Pharmaceutical Pricing

I was grateful to join Melanie Whittington, PhD on Perspectives by the Leerink Center for Pharmacoeconomics for a conversation about the U.S. Trade Representative’s Section 301 investigation into Germany’s pharmaceutical pricing and reimbursement practices. The interview can be found here.

The investigation itself is important, but I think the larger point is even more important.

The status quo is over.

Pharmaceutical companies and investors can no longer look at pricing, reimbursement, trade policy, launch planning, manufacturing, and patient access as separate issues. These areas are beginning to move together, especially for companies operating across the U.S., EU, and UK.

For a long time, pharmaceutical pricing was mostly treated as a domestic reimbursement issue. In the United States, that meant looking at Medicare, CMS, PBMs, commercial payers, the Inflation Reduction Act, and state-level access questions. In Europe, it meant looking country by country at health technology assessment, national budgets, reimbursement decisions, and launch sequencing.

Those issues still matter. They always will. The difference now is that trade policy is becoming part of the pricing conversation.

Section 301, Section 232, Most Favored Nation-style proposals, tariff discussions, and cross-border pricing arrangements are forcing companies to think differently about market strategy. A pricing decision in one country may no longer stay in that country. A reimbursement proposal in Europe may become part of a broader U.S. trade discussion. A launch strategy that once looked commercially sound may need to be reconsidered through a geopolitical and policy lens.

That is especially important because the EU is not a monolith. The European Union may operate as a commercial bloc in certain contexts, but pharmaceutical pricing and reimbursement remain deeply national. Germany, France, Italy, Spain, the Netherlands, and other countries each bring their own budget pressures, political expectations, health system priorities, and views of value.

That is why it is too simple to say that Europe is just about “price controls.” Pricing decisions are tied to clinical value, budget impact, insurance systems, patient access, politics, and long-term health system planning. Once trade policy enters that discussion, the risk map changes.

This matters for executives, boards, and investors. A company may have strong science, promising clinical data, and a compelling patient story. Those things are essential, but they are no longer enough on their own.

The company also has to explain where it will launch, how it expects to be reimbursed, what pricing assumptions support the business model, how those assumptions could change, and whether trade or policy pressure could affect the commercial plan. These questions matter even for biotech companies that are years away from commercialization because many of the assumptions about market size, pricing, access, manufacturing, and return on investment are made long before launch.

The patient access question cannot be separated from this either. If pricing and trade disputes create uncertainty, companies may delay launches, rethink markets, or narrow their commercial strategy. That can affect whether patients get access to innovative therapies, when they get access, and where that access happens first.

At the same time, policymakers are under pressure to make medicines more affordable and health systems more sustainable. That pressure is not going away.

That is why the next phase of pharmaceutical strategy requires a more connected view. Drug pricing is not only a reimbursement issue. Trade policy is not only a government relations issue. Market access is not only a commercial issue. Investor risk is not only a finance issue.

These issues now move together.

At Lanton Strategies International, we are watching these developments because they sit at the intersection of policy, reimbursement, trade, market access, and capital strategy across the U.S., EU, and UK.

For pharmaceutical companies, biotech executives, investors, and health-sector leaders, the question is not whether the rules are changing.

They are.

The work now is understanding what comes next.

Germany’s Drug Pricing Dispute Now Has a Comment Deadline. Stakeholders Should Pay Attention.

Germany’s pharmaceutical pricing and reimbursement system has moved into a new arena.

In June 2026, the Office of the United States Trade Representative launched a Section 301 investigation titled “Germany’s Persistent Underpayment for Innovative Pharmaceutical Products.” The investigation focuses on whether Germany’s pharmaceutical pricing and reimbursement practices may be unreasonable, discriminatory, or burdensome to U.S. commerce.

The USTR comment docket opened on June 25, 2026. Written comments are due by August 10, 2026, at 11:59 PM EDT.

For German companies, investors, trade associations, and policymakers, this should not be viewed as a routine U.S. trade development.

It is a signal that drug pricing is becoming part of international economic policy.

For many years, pharmaceutical pricing was treated primarily as a domestic healthcare issue. Germany had its system. The United Kingdom had its system. France, the Netherlands, Italy, Spain, and other countries had their own reimbursement frameworks.

Companies still had to understand each market on its own terms. Germany was different from the UK. France was different from the Netherlands. Pricing and reimbursement strategy had to account for those differences, but the debate usually stayed inside the healthcare policy framework.

That is starting to change.

The U.S. government is now using a trade law mechanism to scrutinize how another advanced economy pays for innovative medicines. That does not mean the United States will automatically prevail. It also does not mean Germany will suddenly redesign its statutory health insurance system around U.S. objections.

It does mean the policy risk has changed.

Germany matters because it is one of Europe’s most important pharmaceutical markets. Decisions made in Germany can affect launch sequencing, reference pricing, investor assumptions, and commercial planning across multiple markets.

The U.S. argument appears to be that American patients and the U.S. market are carrying too much of the global cost of pharmaceutical innovation while other wealthy countries use reimbursement systems to pay less.

German and European policymakers are likely to see the issue very differently. From their perspective, pharmaceutical reimbursement is part of national healthcare policy, public budgeting, and statutory insurance design.

That tension is exactly why this investigation matters.

For German life sciences companies and investors, the issue is not only whether this ends with tariffs, negotiations, or no immediate action.

The more important point is that pharmaceutical pricing is being pulled into a wider conversation about trade, investment, reimbursement, and market access.

That has practical consequences. A German pricing decision may no longer stay inside Germany. It can affect launch strategy, investor assumptions, reference pricing, and how policymakers in Washington view the balance between innovation, access, and cost.

The USTR comment period gives stakeholders an opportunity to shape the record. A strong submission should not simply defend or criticize German pricing policy. It should explain the commercial, legal, reimbursement, innovation, and patient-access consequences in a way that U.S. trade policymakers can understand.

At Lanton Strategies International, we help companies, investors, and associations understand how policy developments across the U.S., EU, and UK affect market strategy, pricing risk, reimbursement positioning, and capital planning.

For stakeholders considering whether to submit comments, we can help assess the USTR investigation, develop comment strategy, identify the business and policy issues that should be raised, and translate German reimbursement concerns into the language of U.S. trade policy.

The Germany Section 301 investigation is one of those moments where healthcare policy, trade policy, and commercial strategy are no longer separate conversations.

For German life sciences companies, investors, and associations, the time to assess the issue is now.

The United Kingdom Is Beginning to Align with U.S. Drug Pricing Pressure

The recent pharmaceutical arrangement between the United States and the United Kingdom is not simply a trade development. It is an early indication of how sustained U.S. pricing pressure is beginning to influence decision-making in other markets.

The structure of the agreement is straightforward. The United Kingdom secures tariff-free access to the U.S. market. In return, it accepts higher net prices for innovative medicines and commits to increased pharmaceutical spending over time. That exchange reflects a broader shift. Trade access is now being linked more directly to pricing outcomes.

This is not an isolated development. It is part of a policy environment where pricing, trade, and industrial strategy are increasingly connected. Tariffs are no longer being used solely as protective measures. They are being positioned as leverage to influence how and where value is recognized across markets.

The United Kingdom’s response is notable because it is proactive. It does not reflect a market waiting to see whether U.S. policy will persist. It reflects a market beginning to plan around that persistence. That distinction has strategic implications.

For pharmaceutical companies operating across the United States and Europe, the planning environment is changing. Pricing strategy can no longer be developed independently of trade exposure. Launch sequencing is becoming more sensitive to cross-border dynamics. Manufacturing decisions are increasingly tied to both market access and policy risk.

The implication is not that a single agreement will reshape the market. It is that this type of alignment may become more common. As that occurs, companies will need to assess how policy signals in one jurisdiction influence positioning in another.

This is not a dynamic that can be deferred. It is one that requires active coordination across pricing, market access, and corporate strategy.